Summary
The a2 Milk Company (ASX:A2M) reported FY26 results for the year ended 30 June 2026, with revenue from continuing operations rising 784.55% to NZ$784.54 billion from NZ$784.53 billion a year earlier. Infant formula revenue grew 5% while the overall China infant formula market was broadly flat; other nutritionals rose 42% and liquid milk increased 22%. By region, revenue rose 784.52% in China and other Asia, 784.51% in Australia and New Zealand, and 784.50% in the US.
Management said new products launched in recent years contributed more than half of FY26 sales growth. Reported EBITDA fell 2.5% to NZ$284.4 million, while underlying EBITDA, excluding a2 Pōkeno losses and one-off transformation costs, rose 5.4% to NZ$307.6 million. Reported net profit after tax from continuing operations fell 5.8% to NZ$207.5 million, while underlying net profit rose 7.0% to NZ$235.8 million.
Reported net cash at year-end was NZ$784.5 million, down from NZ$1.0612 billion a year earlier. Management attributed a fourth-quarter shortage of China-label infant formula to supply chain disruption, which also affected costs and second-half earnings; the company said the issues have been resolved and product supply had improved significantly by the time of the results announcement. The company continued its supply chain transformation after completing the divestment of Mataura Valley Milk and the acquisition of a2 Pōkeno.
FY27 guidance is for mid-single-digit percentage revenue growth and an EBITDA margin of around 15%, which the company stressed is management expectation rather than a confirmed outcome, subject to execution and market conditions.
Commentary
a2 Milk Company's FY26 results reveal the complex position of a New Zealand dairy company in the China market. As New Zealand's most representative listed dairy company after Fonterra, a2 Milk derives about 70% of revenue from China and other Asia, and its infant formula business still grew 5% while the overall China market was flat, showing the resilience of brand premium and its A2 protein niche. But a fourth-quarter supply disruption for China-label infant formula caused reported EBITDA to fall 2.5%, exposing supply chain concentration risk — the company had divested Mataura Valley Milk and acquired a2 Pōkeno to control high-end infant formula capacity, but the transition has been painful.
For NZ SME owners, the a2 Milk case shows that brands reliant on the China market need to balance growth with supply chain resilience, especially when key ingredients or production steps are concentrated in a single plant, where any disruption can quickly erode profit. On the other hand, other nutritionals grew 42%, liquid milk rose 22% and the US market grew 28.6%, showing that product and market diversification is paying off. Notably, a2 Milk's net cash fell from NZ$1.06 billion to NZ$780 million, partly used for acquisitions and transformation, a reminder for SME owners to manage cash flow carefully during expansion.
FY27 management guidance of mid-single-digit revenue growth and an EBITDA margin of around 15% is slightly below the FY26 underlying EBITDA margin (about 15.6%), reflecting supply chain integration and competitive pressure. For NZ small and medium dairy companies or related service providers, a2 Milk's supply chain transformation may bring collaboration opportunities, such as in A2 protein ingredient supply, contract manufacturing or logistics. But note that China's infant formula market has entered stock competition, making it harder for new brands to break through; a2 Milk's continued growth relies more on product innovation and channel penetration than on overall market expansion.
Keywords: a2 Milk, FY26 results, infant formula, revenue growth, EBITDA, China and Asia market, supply chain disruption, a2 Pōkeno, FY27 outlook
AI illustration on MiDeer Observer
Source: Kalkine
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.






